Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells
Journal
Anticancer Research
Journal Volume
31
Journal Issue
6
Pages
2231-2239
Date Issued
2011
Author(s)
Abstract
Background: The effects of combined valproic acid (VPA) and celecoxib treatment on cancer cells have not been reported. In this study, we examined the effects of VPA and celecoxib, alone and combined, on human SH-SY5Y neuroblastoma cells. Materials and Methods: The cytotoxicity effects of VPA, celecoxib, and combined VPA and celecoxib treatment on neuroblastoma cells were studied. The apoptotic fraction and the cell cycle distribution of neuroblastoma cells were analyzed by flow-activated cell sorter analysis. Western blot analysis was used to investigate the expression of cyclooxygenase-2, p53, 14-3-3σ, p21, p27, Bcl-2 and Bax in neuroblastoma cells treated with various regimens. Results: Combined VPA and celecoxib treatment caused more cytotoxicity and apoptosis in neuroblastoma cells than individual drug treatment (p<0.05). In addition, combination treatment caused more neuroblastoma cells to accumulate in the G0/G1 phase of the cell cycle (p<0.04) and induced higher p21 and p27 expression than individual drug treatment or control. Conclusion: Combined VPA and celecoxib treatment induced more cytotoxicity and apoptosis in neuroblastoma cells than individual drug treatment. The effects were probably related to the increased p21 and p27 expression, and G0/G1 accumulation of neuroblastoma cells.
Subjects
Apoptosis; Celecoxib; Cytotoxicity; Neuroblastoma; Valproic acid
SDGs
Other Subjects
celecoxib; cyclooxygenase 2; protein Bax; protein bcl 2; protein p21; protein p27; protein p53; stratifin; valproic acid; antineoplastic activity; apoptosis; article; cancer cell destruction; cell cycle arrest; cell cycle G0 phase; cell cycle G1 phase; cell cycle G2 phase; cell cycle M phase; cell cycle S phase; chemosensitivity; concentration response; controlled study; drug cytotoxicity; drug potentiation; human; human cell; neuroblastoma; neuroblastoma cell; priority journal; protein expression; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; G0 Phase; G1 Phase; Humans; Neuroblastoma; Pyrazoles; Sulfonamides; Valproic Acid
Type
journal article